Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

Angiogenesis inhibitors, study points to limitations, solutions

A new generation of cancer drugs designed to starve tumors of their blood supply - called "angiogenesis inhibitors"-succeeds at first, but then promotes more invasive cancer growth-sometimes with a higher incidence of metastases, according to a new study in animals.

2 Mar 2009

Researchers examine role of high cholesterol in prostate cancer

Current research suggests that lowering cholesterol may block the growth of prostate tumors.

23 Feb 2009

Tiny cell cultivation chamber of silicon plastic opens new potential in tumor research

Researchers at Uppsala University have developed a new tool that makes it possible to study the signals in the body that control the generation of blood vessels.

22 Feb 2009

Molecules self-assemble to provide new therapeutic treatments

Researchers in the laboratory of Samuel I. Stupp at Northwestern University have an interesting approach for tackling some major health problems: gather raw materials and then let them self-assemble into structures that can address a multitude of medical needs.

16 Feb 2009

$8.2 million for cancer research

Last Friday, Minister for Health and Ageing, Nicola Roxon announced that fifteen of Australia's leading health and medical research teams have won a share of more than $108 million in National Health and Medical Research Council's program grants scheme.

9 Feb 2009

Fibroblasts invade at a snail's pace

A transcription factor known to drive the formation of fibroblasts during development also promotes their ability to invade and remodel surrounding tissues, report Rowe et al. in the February 9, 2009 issue of the Journal of Cell Biology.

2 Feb 2009

Stress may speed growth of melanoma tumors

For patients with a particularly aggressive form of skin cancer - malignant melanoma - stress, including that which comes from simply hearing that diagnosis, might amplify the progression of their disease.

2 Feb 2009

Biodegradable nanoprobe images new blood vessel growth

Angiogenesis, the growth of new blood vessels, plays a critical role in several chronic human diseases, including metastatic cancer. In fact, several new anticancer therapies are designed to starve tumors by shutting down angiogenesis, but the lack of a good assay for quantifying angiogenesis in the body has hampered the development of effective antiangiogenesis therapies.

18 Jan 2009

Control of blood vessels a possible weapon against obesity

Mice exposed to low temperatures develop more blood vessels in their adipose tissue and metabolise body fat more quickly, according to a new study from Karolinska Institutet. Scientists now hope to learn how to control blood vessel development in humans in order to combat obesity and diabetes.

7 Jan 2009

Cylene Pharmaceuticals starts CX-4945 trial - first-in class inhibitor of CK2

Cylene Pharmaceuticals announced today that it has initiated a Phase I clinical trial of its oral CK2 protein kinase inhibitor, CX-4945, in patients with advanced solid tumors, Castleman's disease, or multiple myeloma.

5 Jan 2009

New anti-tumor gene called SARI

Researchers from Virginia Commonwealth University have identified a new anti-tumor gene called SARI that can interact with and suppress a key protein that is overexpressed in 90 percent of human cancers.

16 Dec 2008

New bone and tissue regeneration technique

Using stem cell lines not typically combined, researchers at Columbia University Medical Center have designed a new way to "grow" bone and other tissues.

15 Dec 2008

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

New data released demonstrates that the addition of Zometa (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease.

14 Dec 2008

Researchers focus on phosphoinositide 3-kinase pathway in cancer research

Researchers are taking a closer look at the phosphoinositide 3-kinase (PI3-kinase) pathway as studies continue to demonstrate that inhibiting this biological route suppresses tumor growth, reports Genetic Engineering & Biotechnology News (GEN ).

5 Dec 2008

Prostate cancer tumors promote nerve growth

Prostate cancer - and perhaps other cancers - promotes the growth of new nerves and the branching axons that carry their messages, a finding associated with more aggressive tumors, said researchers from Baylor College of Medicine in the first report of the phenomenon that appears today in the journal Clinical Cancer Research.

1 Dec 2008

CardioVascular BioTherapeutics doses first patient in trial for severe coronary heart disease

CardioVascular BioTherapeutics, Inc. , announced today that it has dosed the first patient in North America (NA) as part of its ACORD Phase II clinical trial to treat patients with severe coronary heart disease.

25 Nov 2008

Mechanisms of cardiovascular disease and cancer give clues to new therapies

Cardiovascular conditions leading to heart attacks and strokes are treated quite separately from common cancers of the prostate, breast or lung, but now turn out to involve some of the same critical mechanisms at the molecular level.

21 Nov 2008

New approach to stopping germs

Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.

20 Nov 2008

Nanoparticle targets melanoma with siRNA

Research has shown that a particular receptor for the blood protein thrombin is overexpressed by highly metastatic melanoma cells.

20 Nov 2008

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

19 Nov 2008